Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

  title={Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.},
  author={Stuart D. Cook and Thomas P. Leist and Giancarlo Comi and Xavier Montalban and Gavin Giovannoni and Axel Nolting and Christine Hicking and Andrew R. Galazka and Elke Sylvester},
  journal={Multiple sclerosis and related disorders},

Figures and Tables from this paper

Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Subcutaneous cladribine with increased cumulative maintenance dosage was associated with disease stability and favorable safety over a prolonged period of follow-up (up to 20 years) in RMS patients.

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

A review of all safety data, including lymphopenia, infections, and malignancies, is provided based on data from all trials in patients with MS, including the initial parenteral formulation studies.

CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.

Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy

Observational data suggest a disease-modifying effect in this cohort of relapsing MS patients characterised by older and more disabled patients, and an overall increasing trend prior to cladribine treatment which was reduced during the 2-year post-treatment.

Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates

The IRT approach may be especially useful for patients with highly active MS insufficiently responsive to treatment with a first-line DMT, those who are likely to adhere poorly to a continuous therapeutic regimen, treatment-naïve patients with high disease activity at first presentation, or patients planning a family who are prepared to wait until at least 6 months after the end of treatment.

Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4

A panel of neurologists and a neuroradiologist experienced in MS treatment/monitoring evaluated clinical trial data and real-world evidence and proposed recommendations for the management of cladribine-treated patients beyond year 4 and found continuous monitoring of disease activity during the treatment-free period is important.

Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study

Previous data about cladribine effectiveness on disease activity and disability worsening and information on response predictors that might inform therapeutic choices are confirmed and provided.

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review

Cladribine tablets represent a selective, high-efficacy, oral form of IRT for patients with MS that targets lymphocytes and spares innate immune cells and is associated with a lower monitoring burden than many other DMTs, while short dosing periods can help to improve adherence.



Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study

Patients with HDA showed clinical and MRI responses to Cladribine Tablets 3.5 mg/kg that were generally better than, or at least comparable with, the outcomes seen in the overall CLARITY population.

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

The safety and tolerability profile observed in the CLARITY study together with the reported efficacy support the potential for cladribine tablets as an MS therapy.

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

Cladribine tablets treatment for 2’ years followed by 2 years’ placebo treatment produced durable clinical benefits similar to 4’years of cladribine treatment with a low risk of severe lymphopenia or clinical worsening.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks, and the benefits need to be weighed against the risks.

Efficacy of Cladribine Tablets as Add-On to IFN-beta Therapy in Patients with Active Relapsing MS: Final Results from the Phase II ONWARD Study (P3.029)

In patients with active relapsing MS with breakthrough disease while on IFN-β therapy (including SPMS with ongoing relapses), treatment with cladribine tablets added on to IFn-β demonstrated significant efficacy benefits.

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

Preliminary data indicate that cladribine is effective for the treatment of MS and has a promising safety and tolerability profile, which makes it suitable for intermittent oral dosing, which is expected to offer benefits for patient satisfaction and therapeutic adherence.

MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study

MRI-measured disease activity was greatly reduced by both doses of cladribine tablets, with consistent effect across clinically relevant patient populations, and these findings add to the scientific understanding of the neurological impact of this therapeutic modality in patients with RRMS.

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study

Despite of the criteria used to define CIS or MS, 3.5 mg/kg cladribine tablets are effective in patients with a first clinical demyelinating attack, and the risk of conversion to clinically definite multiple sclerosis (CDMS) is reduced.